These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

134 related items for PubMed ID: 10758791

  • 1. Effect of sequential estrogen/progestin treatment on biochemical vasoactive markers in postmenopausal women comparing oral and transdermal application.
    Seeger H, Mueck AO, Teichmann AT, Lippert TH.
    Clin Exp Obstet Gynecol; 2000; 27(1):17-20. PubMed ID: 10758791
    [Abstract] [Full Text] [Related]

  • 2. Effect on biochemical vasoactive markers during postmenopausal hormone replacement therapy: estradiol versus estradiol/dienogest.
    Mueck AO, Seeger H, Lüdtke R, Gräser T, Wallwiener D.
    Maturitas; 2001 May 30; 38(3):305-13. PubMed ID: 11358648
    [Abstract] [Full Text] [Related]

  • 3. [Effect of transdermal versus oral estradiol administration on the excretion of vasoactive markers in postmenopausal women].
    Mueck AO, Seeger H, Lippert TH.
    Gynakol Geburtshilfliche Rundsch; 2000 May 30; 40(2):61-7. PubMed ID: 10971087
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Urinary excretion of vasoactive markers following estrogen replacement therapy in postmenopausal women.
    Mueck AO, Seeger H, Lippert C, Wallwiener D.
    Int J Clin Pharmacol Ther; 2000 Aug 30; 38(8):381-6. PubMed ID: 10984011
    [Abstract] [Full Text] [Related]

  • 6. Low-dose continuous combinations of hormone therapy and biochemical surrogate markers for vascular tone and inflammation: transdermal versus oral application.
    Mueck AO, Genazzani AR, Samsioe G, Vukovic-Wysocki I, Seeger H.
    Menopause; 2007 Aug 30; 14(6):978-84. PubMed ID: 17595593
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Transdermal sequential and continuous hormone replacement regimens with estradiol and norethisterone acetate in postmenopausal women: effects on the endometrium.
    Johannisson E, Holinka CF, Arrenbrecht S.
    Int J Fertil Womens Med; 1997 Aug 30; 42 Suppl 2():388-98. PubMed ID: 9397386
    [Abstract] [Full Text] [Related]

  • 9. Positive effects on cardiovascular and breast metabolic markers of oral estradiol and dydrogesterone in comparison with transdermal estradiol and norethisterone acetate.
    Campagnoli C, Colombo P, De Aloysio D, Gambacciani M, Grazioli I, Nappi C, Serra GB, Genazzani AR.
    Maturitas; 2002 Apr 25; 41(4):299-311. PubMed ID: 12034517
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The effect of various menopausal hormone therapies on markers of inflammation, coagulation, fibrinolysis, lipids, and lipoproteins in healthy postmenopausal women.
    Zegura B, Guzic-Salobir B, Sebestjen M, Keber I.
    Menopause; 2006 Apr 25; 13(4):643-50. PubMed ID: 16837886
    [Abstract] [Full Text] [Related]

  • 12. A randomized, double-blind, multicentre study comparing the clinical effects of two sequential estradiol-progestin combinations containing either desogestrel or norethisterone acetate in climacteric women with estrogen deficiency symptoms.
    Saure A, Hirvonen E, Milsom I, Christensen A, Damber MG.
    Maturitas; 1996 May 25; 24(1-2):111-8. PubMed ID: 8794442
    [Abstract] [Full Text] [Related]

  • 13. Effects of postmenopausal estrogen/progestin replacement therapy on LDL particles; comparison of transdermal and oral treatment regimens.
    Lahdenperä S, Puolakka J, Pyörälä T, Luotola H, Taskinen MR.
    Atherosclerosis; 1996 May 25; 122(2):153-62. PubMed ID: 8769679
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Influence of norethisterone acetate and estradiol on the serotonin metabolism of postmenopausal women.
    Mueck AO, Seeger H, Kasspohl-Butz S, Teichmann AT, Lippert TH.
    Horm Metab Res; 1997 Feb 25; 29(2):80-3. PubMed ID: 9105905
    [Abstract] [Full Text] [Related]

  • 16. Comparison of continuous and sequential transdermal progestogen with sequential oral progestogen in postmenopausal women using continuous transdermal estrogen: vasomotor symptoms, bleeding patterns, and serum lipids.
    Rozenberg S, Ylikorkala O, Arrenbrecht S.
    Int J Fertil Womens Med; 1997 Feb 25; 42 Suppl 2():376-87. PubMed ID: 9397385
    [Abstract] [Full Text] [Related]

  • 17. Hormone replacement therapy lowers plasma Lp(a) concentrations. Comparison of cyclic transdermal and continuous estrogen-progestin regimens.
    Taskinen MR, Puolakka J, Pyörälä T, Luotola H, Bjäörn M, Kääriänen J, Lahdenperä S, Ehnholm C.
    Arterioscler Thromb Vasc Biol; 1996 Oct 25; 16(10):1215-21. PubMed ID: 8857916
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Tibolone, transdermal estradiol or oral estrogen-progestin therapies: effects on circulating allopregnanolone, cortisol and dehydroepiandrosterone levels.
    Pluchino N, Genazzani AD, Bernardi F, Casarosa E, Pieri M, Palumbo M, Picciarelli G, Gabbanini M, Luisi M, Genazzani AR.
    Gynecol Endocrinol; 2005 Mar 25; 20(3):144-9. PubMed ID: 16019353
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.